Medexus and Medac estimate it will take up to a year to collect and submit all data requested by the FDA for the resubmitted NDA for treosulfan.
Announced Research Updates
Oramed announced that in the 26-week, 710 patient, Phase III, ORA-D-013-1 trial, oral insulin did not improve HbA1c or fasting plasma glucose compared to placebo in patients with type 2 diabetes that was not controlled by at least one antihyperglycemic agent.
Published Research Updates
In the 12-week, 153-patient, Phase IIb, D1AMOND trial, treatment with ecopipam reduced the YGTSS-TTS by 3.44 points compared to placebo in patients aged 6 to 17 years with Tourette syndrome.
Subscribers received a total of EIGHT study results this week. Contact us today for a subscription.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right